Background: The aim of this cross-sectional study was to analyze the monocyte-tohigh-density lipoprotein ratio (MHR) as an inflammatory marker in patients with psoriatic arthritis (PsA) and healthy controls (HCs), as well as to determine the association between MHR and PsA severity.Methods: This cross-sectional study included patients with PsA (n=66) and age and sex-matched HCs (n=68). Sociodemographic data and laboratory parameters were recorded in the study group. Disease Activity in PSoriatic Arthritis (DAPSA) was used to assess disease activity, while the Health Assessment Questionnaire (HAQ) was used for general health assessments. Disease Activity in PSoriatic Arthritis and HAQ were evaluated in the patient group. We compared sociodemographic, laboratory parameters, and the MHR between patients with PsA and HCs. Factors influencing MHR were assessed by regression analysis.Results: Patients with PsA revealed increased MHR compared to HCs (P=.025). In regression analysis, a DAPSA score of 15 or higher results in a 3.08 unit rise in the MHR, compared to a DAPSA score of 14 or below. In individuals with coronary artery disease (CAD), MHR increases by 7.56 units. Patients with moderate–severe PsA (DAPSA ≥ 15) had significantly elevated levels of C-reactive protein, erythrocyte sedimentation rate, and MHR compared to patients with remission-mild PsA (DAPSA ≤ 14) (P < .001,<.001, .026, respectively).Conclusions: Monocyte-to-high-density lipoprotein ratio can be used as an inflammatory marker in the follow-up of patients with PsA. Patients with PsA without evidence of active disease should also be evaluated for CAD in the presence of a high MHR value.Cite this article as: Varkal G, Türk I, Yetişir A, Doğan Ağbuga Ö, Mete B, Özbek S. The relationship between the monocyteto-high-density lipoprotein-cholesterol ratio and disease activity in patients with psoriatic arthritis. Eur J Rheumatol. 2025, 12(2), 0052, doi: 10.5152/eurjrheum.2025.24052.

Disease and treatment-related comorbidities in rheumatoid arthritis - Journal of Turkish Society for Rheumatology

Purpose: The aim of this study was to detect infections requiring hospitalization in patients with ANCA-associated vasculitis (AAV). Materials and Methods: This is a single-center, retrospective study conducted in Turkish patients with AAV. Infection episodes requiring hospitalization, reproducing pathogens, laboratory findings, immunosuppressive treatments given for the treatment of vasculitis, and the relationship with the infection were evaluated. Results: Seventy-four patients diagnosed with AAV were included in the study. Hospitalization due to infection was observed in 36 of the patients. The coexistence of diabetes mellitus (DM) was found to be significantly higher in the infected patient group. Cyclophosphamide (CYC) treatment found to increase risk of infection. More than 80% of the infected patient group presented with renal involvement (80.6%). A total of 68 infectious episodes were seen in 36 patients. The most common involvement of infection was the respiratory tract with a rate of 70.6%. Gram-negative bacteria were the most common pathogen, especially Pseudomonas aeruginosa. With the effect of the pandemic, SARS-CoV-2 has come to the fore among viral infections. Aspergillosis was the most frequently detected among fungal infections. Besides, aspergillosis was the cause of 85.7% (6 episodes) of fungal infections. Lymphopenia was observed in 76.5% of the infection episodes. 57.4% of infections developed in the first year of the induction therapy. The most frequently used immunosuppressive therapy for the treatment of vasculitis in infectious episodes was CYC (41.2%). Conclusion: Managing infections during the vasculitis treatment is crucially important. Lymphopenia, kidney involvement, DM and immunosuppressive therapy are factors that increase the risk of infection. Clinicians should take preventive measure especially for respiratory tract infections and gram-negative bacteria as pathogens.

Analjezikler, Non-Steroid Anti-İNFLAMATUAR İlaçlar ve Kortikosteroidler Duygu KURTULUŞ Biyolojik Olmayan Hastalık Modifiye Edici Antiromatizmal ilaçlar Ali Nail DEMİR Romatolojide Biyolojik Tedavi Ajanları İsmail UÇAR İmmunsupresifler ve Diğer İlaçlar Önay GERÇİK Romatolojide İntravenöz İmmünoglobulin Uygulamaları Hüseyin Ali ÖZTÜRKAlper YILDIRIM Romatolojide Plazmaferez Uygulamaları Alper YILDIRIM Erken Artrit ve Palindromik Romatizma: Güncel Tedavi Neslihan GÖKÇEN Romatoid Artrit: Güncel Tedavi Zeynep KAYA Meryem CAN Romatoid Artritte Ekstra-Artiküler Tutulum Tedavisi Zübeyde UĞURLU Atalay DOĞRU Tekrarlayıcı Seronegatif Pİtting Ödemli Simetrik Sinovit (R3SPE) Sendromu Tedavi Yönetimi Berkan ARMAĞAN Erişkin Başlangıçlı Still Hastalığına Güncel Yaklaşım Ahmet KOR Şükran ERTEN Enfeksiyöz Artritler: Bakteriyel Artritler, Lyme Artriti, Viral Artritler, Mikobakteriyel, Brucella, Fungal Ve Parazitik Artritler: Güncel Tedavi Fatma TUNCER KURU Ankilozan Spondilit ve Non-Radyografik Aksiyel Spondiloartrit: Güncel Tedavi Dilek SOLMAZ Periferik Spondiloartrit: Güncel Tedavi Fatih SARITAŞ Psöriatik Artrit: Güncel Tedavi Selda ÇELİK Enteropatik Artrit Tedavisi Mete PEKDİKER Reaktif Artrit: Güncel Tedavi Özgül SOYSAL GÜNDÜZ Jüvenil İdyopatik Artrit Tedavisinde Güncel Yaklaşımlar Kenan BARUT Elif KILIÇ KÖNT Özgür KASAPÇOPUR Sistemik Lupus Eritematozusda Güncel Tedavi Hamide Kart KÖSEOĞLU Sjögren Sendromunda Güncel Tedavi Yaklaşımları Pınar TALU ERTEN Antifosfolipid Sendromu Tedavisi Pınar AKYÜZ DAĞLI Ahmet OMMA Gebelikte Sistemik Lupus Eritematozus ve Antifosfolipid Antikor Sendromu: Güncel Tedavi Senar ŞAN Ayten YAZICI Kutanöz Lupus Eritematosus: Güncel Tedavisi Tuğba TEHÇİ Sistemik Skleroz Tedavisi Yasemin YALÇINKAYA Raynaud Fenomeninin Güncel Tedavisi Duygu TEMİZ KARADAĞ İdiopatik İnflamatuar Myopati Güncel Tedavi Figen TARHAN Anti-Sentetaz Sendromu Emel GÖNÜLLÜ Mix Konnektif Doku Hastalığında Güncel Tedavi İpek TÜRK Undiferansiye Bağ Dokusu Hastalığı ve Overlap Sendromlar Güncel Tedavi Derya KAŞKARİ Poliarteritis Nodosa Güncel Tedavisi Esra KAYACAN ERDOĞAN Dev Hücreli Arterit ve Polimyaljiya Romatika Tedavisi Vedat GERDAN Granülomatöz Polianjiitis’te Güncel Tedavi Özlem DOĞAN AĞBUGA Diğer Anca İlişkili Vaskülitlerde Güncel Tedavi Emrah KOÇ Takayasu Arteriti Güncel Tedavisi Sema KAYMAZ TAHRA Fatma ALİBAZ ÖNER Klinik Tutulumlara Göre Behçet Hastalığında Güncel Tedavi Yüksel MARAŞ Kawasaki Hastalığı Güncel Tedavi Rabia Miray KIŞLA EKİNCİ İmmun Kompleks Küçük Damar Vaskülitlerinde Güncel Tedavi Elif EDİBOĞLU Sarkoidoz: Güncel Tedavi Müge AYDIN TUFAN Relapsing Polikondrit Suade Özlem BADAK IgG4 İlişkili Hastalık: Güncel Tedavi Nazife Şule YAŞAR BİLGE Timuçin KAŞİFOĞLU Ailevi Akdeniz Ateşi: Güncel Tedavi Zeynep TOKER DİNÇER Serdal UĞURLU Henoch Schönlein Purpurası (HSP) Özge Altuğ GÜCENMEZ FMF Dışı Otoenflamatuar Hastalıklar: Güncel Tedavi Amra ADROVİÇ Mehmet YILDIZ Özgür KASAPÇOPUR Otoinflamatuar Hastalıklarda Aa Amiloidoz Güncel Tedavi Safiye BAKKALGerçek CAN Gut: Güncel Tedavi Gezmiş KİMYON CPPD Güncel Tedavi Fatih Necip ARICI Alper YILDIRIM Konnektif Doku Hastalığı İlişkili Pulmoner Arteriyel Hipertansiyon Tedavisi Alper SARI Romatolojik Hastalıklarda İnterstisyel Akciğer Hastalığı: Güncel Tedavi Zevcet YILMAZ Romatolojik Hastalıklarda Aşılama Mehmet Ali AŞIK Gebe, Emziren Ve Gebelik Planı Olan Romatoloji Hastalarında Paternal ve Maternal İlaç Kullanımı Sercan GÜCENMEZ